This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
Patients who received previous RT to the prostate bed +/- pelvic nodal regions
Prostate-bed recurrence identified by biopsy and/or MRI and/or PSMA-PET scan
At least two continuous PSA elevations post RT and PSA above 0.2 ng/dl
With or without ADT PSA doubling time from nadir greater than 6 months
Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases
History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT
Any contraindications to MR and/or brachytherapy
University Health Network, Toronto
Lead sponsor